Radiation therapy and medical technology innovation by Accuray
AlignRT InBore integrates with Accuray Helical to support vendor-agnostic treatment advances
Accuray has announced the integration of AlignRT InBore with its Helical platform, aiming to advance flexible and vendor-agnostic solutions for modern treatment workflows. The company stated ...
Accuray unveils innovative RT solutions at Lyon scientific conference
Accuray is participating live at Booth 8 during the 64th Journées Scientifiques de Physique Médicale in Lyon. The company is engaging with attendees to demonstrate its latest advances in ...
Accuray to host webinar on Chiang Mai University TomoTherapy clinical data
Accuray announced a live webinar on June 25 to review 14 years of TomoTherapy clinical experience at Chiang Mai University with Dr. Nobnop. The session will be moderated by Lee Goddard and is ...
Accuray: CyberKnife radiosurgery halts progression in pituitary adenoma per Carlo Besta Institute study
Accuray reports that the Carlo Besta Neurological Institute has achieved disease stability in patients with non-functioning pituitary adenoma using multi-session radiosurgery with the CyberKnife ...
CyberKnife treatment delivers full local control for uveal melanoma at ISRS2026, with favorable safety profile
Accuray reported that in a retrospective analysis presented at ISRS2026, all 68 uveal melanoma patients treated with CyberKnife achieved local tumor control at a mean follow-up of 46.5 months. ...
Accuray presents single day prostate radiotherapy approach at ESTRO26 with CyberKnife
Accuray has introduced a novel strategy for prostate cancer treatment, unveiling the PRO-FAST protocol at ESTRO26 in Milan. The approach utilizes single-day, single-fraction radiotherapy for ...
Radixact platform draws attention to pediatric radiotherapy progress at ESTRO26
Accuray hosted a presentation at ESTRO26 featuring Dr Liam Herbert from Queen Elizabeth Hospital Birmingham, UK, highlighting developments in pediatric radiotherapy using the Radixact platform. ...
Accuray reports 10 percent xerostomia rate with over 70 months follow up in helical TomoTherapy study
Accuray has released prospective data from a study involving 266 patients with more than 70 months of follow up, indicating that comprehensive salivary gland sparing helical TomoTherapy may ...
CyberKnife therapy delivers promising early tumor control for 50 acoustic neuroma patients, Accuray reports
Accuray reported clinical results from Ospedale Isola Tiberina - Gemelli Isola in Rome, where 50 acoustic neuroma patients received treatment using CyberKnife in either one or three fractions. ...
Accuray brings AI in radiotherapy to ESTRO stage focusing on clinical performance and ethics
Accuray is set to present the integration of artificial intelligence in radiotherapy at the ESTRO event on Monday. The discussion will cover aspects such as clinical performance, the legal ...
Accuray showcases Radixact system for paediatric radiotherapy at ESTRO conference
Accuray introduced its Radixact system for paediatric radiotherapy live at the ESTRO Stage. The presentation is part of the ESTRO26 event, with the company highlighting applications of its ...
Accuray enables National Cancer Center Myanmar to treat 18 patients with Radixact system in two days
Accuray announced that the National Cancer Center in Myanmar has successfully launched its Radixact system, treating its first 18 patients over two consecutive days. The center managed eight cases ...
CyberKnife and helical platforms demo bookings now available at ESTRO26 from Accuray
Accuray is inviting attendees to book one-on-one demonstrations of its CyberKnife stereotactic and helical radiation therapy platforms during the ESTRO26 event. The company highlights limited ...
Accuray study finds organ deformation risk surpasses tracking uncertainty in pancreatic SBRT
A new study referenced by Accuray reports that, in pancreatic stereotactic body radiotherapy (SBRT) using CyberKnife and Synchrony, the proximity of treatment targets to organs at risk (OARs) is a ...
Accuray FRAME-PROSTATE study finds TomoTherapy delivers strong long-term survival in prostate cancer patients
Accuray has released 10-year results from the FRAME-PROSTATE trial, demonstrating that TomoTherapy image-guided, moderate hypofractionation radiotherapy after prostatectomy yields excellent ...
Accuray study finds helical TomoTherapy lowers risk and severity of temporal lobe injury in NPC cohort
Accuray has released findings from a radiation oncology study indicating that helical TomoTherapy significantly reduces the incidence and severity of radiation-induced temporal lobe injury, ...
Radixact and Helix boost flexible helical radiotherapy, Accuray introduces advanced options at ESTRO26
Accuray introduces enhanced flexibility and confidence in helical treatment delivery with its Radixact and Accuray Helix solutions at ESTRO26. The company is focusing on advancing radiotherapy ...
Accuray study links helical TomoTherapy to significantly lower xerostomia in advanced nasopharyngeal carcinoma
A recent large-scale propensity score–matched clinical study from Accuray finds that patients with locally advanced nasopharyngeal carcinoma undergoing helical TomoTherapy experience ...
Clinica Moncucco paper reports robust optical sensor LOT reconstruction with 1 ms precision, Accuray asserts
Accuray has congratulated Clinica Moncucco for publishing a Medical Physics paper that achieved robust optical sensor leaf open time (LOT) reconstruction using the Radixact platform, reaching 98.1 ...
Accuray opens registration for prostate cancer SBRT webinar featuring Ah Ram Chang and Sean Collins
Accuray invites medical professionals and interested participants to register for its upcoming SBRT for prostate cancer webinar. The event will take place on April 29 at 7:30am EDT, 1:30pm CEST, ...
Accuray finds individualized dose margins reduce OAR risk in nasopharyngeal carcinoma
Accuray presents new findings suggesting that uniform PTV margins may not always ensure adequate coverage in nasopharyngeal carcinoma treatment. The research shows that daily MVCT with ...
